Oct 19th, 2022
Today's Late-Breaking Science and Featured Science
Saturday's cutting-edge abstracts seek to change clinical practice and promote findings in heart failure.
LBS.01. The Main Event: Changing Clinical Practice
Saturday, Nov. 5 | 9:30-10:30 a.m. | Main Event I
- Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial (TRANSFORM-HF)
- Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension (DCP)
- A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease (PROMINENT)
LBS.02. Breakthrough Strategies in the HF Journey
Saturday, Nov. 5 | 3-4 p.m. | Main Event I
- First-in-Human in vivo CRISPR/Cas9 Editing of the TTRGene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- A Patient Risk-Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
- Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial
- IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction (IRONMAN)
Learn more about #AHA22 Late-Breaking Science and Featured Science.